Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Jul 29;6(7):e450.
doi: 10.1038/bcj.2016.62.

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

Y Chen  1 , M Ooi, S F Lim  2 , A Lin  2 , J Lee  2 , C Nagarajan  1 , C Phipps  1 , Y S Lee  1 , N F Grigoropoulos  1 , Z Lao  1 , S Surendran  1 , E M Teh  1 , Y T Goh  1 , W J Chng  2 , S K Gopalakrishnan  1
Affiliations
Case Reports

Thrombotic microangiopathy during carfilzomib use: case series in Singapore

Y Chen et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

SKG has received research funding from Amgen. The remaining authors declare no conflict of interest.

References

    1. Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol. 2011; 7: 607–12. Available from http://www.futuremedicine.com/doi/abs/10.2217/fon.11.42. - PMC - PubMed
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142–152. - PubMed
    1. Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD et al. US Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 4559–4563. - PubMed
    1. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753–1761. - PMC - PubMed
    1. Hobeika L, Self SE, Velez JCQ. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 2014; 15: 156. - PMC - PubMed